Novo and Martin Marietta contributed to the biocement producer’s latest round, which was led by 2150 and which will fund hiring and technology development.

US-headquartered biological construction material developer Biomason secured $65m in series C funding yesterday from investors including pharmaceutical firm Novo and building materials provider Martin Marietta. 2150 led the round, which also featured venture capital firm Celesta Capital and energy and commodities trading firm Hartree Partners. Founded in 2012, Biomason provides cement created with materials grown…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.